Inhibikase Therapeutics (IKT) Accumulated Depreciation & Amortization (2022 - 2025)
Historic Accumulated Depreciation & Amortization for Inhibikase Therapeutics (IKT) over the last 4 years, with Q3 2025 value amounting to $117224.0.
- Inhibikase Therapeutics' Accumulated Depreciation & Amortization rose 13370.95% to $117224.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $117224.0, marking a year-over-year increase of 13370.95%. This contributed to the annual value of $56725.0 for FY2024, which is 8627.06% up from last year.
- As of Q3 2025, Inhibikase Therapeutics' Accumulated Depreciation & Amortization stood at $117224.0, which was up 13370.95% from $93537.0 recorded in Q2 2025.
- In the past 5 years, Inhibikase Therapeutics' Accumulated Depreciation & Amortization registered a high of $170970.0 during Q2 2023, and its lowest value of $1681.0 during Q3 2022.
- For the 4-year period, Inhibikase Therapeutics' Accumulated Depreciation & Amortization averaged around $54854.8, with its median value being $43590.0 (2024).
- Per our database at Business Quant, Inhibikase Therapeutics' Accumulated Depreciation & Amortization soared by 132088.04% in 2023 and then tumbled by 7450.43% in 2024.
- Over the past 4 years, Inhibikase Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $6723.0 in 2022, then surged by 352.97% to $30453.0 in 2023, then skyrocketed by 86.27% to $56725.0 in 2024, then surged by 106.65% to $117224.0 in 2025.
- Its last three reported values are $117224.0 in Q3 2025, $93537.0 for Q2 2025, and $69379.0 during Q1 2025.